MyMD Pharmaceuticals, Inc., recently signed a Cooperation and Purchase Agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Company to purchase Oravax’s oral COVID-19 vaccine.
Their order includes 10 million doses. This deal is a “trial run” on a mass scale, with incremental payments for the moment and potential follow-ups to be negotiated as the deal proceeds, Business Wire reported.
"A discussion of these and other factors with respect to MyMD is set forth in the Quarterly Report on Form 10-Q for the quarterly period that ended Sept. 30, 2021, filed by MyMD on Nov. 12, 2021 (as amended on Nov. 15, 2021)," a press release read. "Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise."
Per the agreement, Tan Thanh Holdings will sell Oravax’s oral vaccine in development throughout the Association of Southeast Asian Nations (ASEAN). The ASEAN includes Vietnam, Brunei, Cambodia, Indonesia, Laos, Thailand, Malaysia, Myanmar, and Singapore. The COVID-19 pill is still in the clinical trial phase, with plans in place for large-scale distribution and scaling. MyMD Pharmaceuticals hopes to target current and future coronavirus variants.